Under the Influence?
By Kent Sepkowitz,
Slate
| 09. 10. 2007
Drug companies, medical journals, and money
Scientific fraud comes in several varieties. Data can be fabricated, ideas swiped, experiments gamed. One dramatic version is the too-late revelation that an investigator was drinking at the watering hole of a pharmaceutical company when he or she published an article about the wonders of a certain drug, produced by the watering hole's operators.
To prevent such embarrassments, medical journals now run authors through the wringer to potentially illuminate their often-cozy relationships with pharmaceutical companies. We writers complete an extensive conflict-of-interest form describing any payments received for lectures or advice, research grants, and personal or family financial interests. This information is then included at the end of the published article, allowing the reader to judge whether an author might have been working under the influence.
Although onerous to coordinate (and annoying to complete), this approach is an important first step in preventing unseemly trysts between doctors and the pharmaceutical industry. But it does not go far enough because it ignores an even more conspicuous denizen of the watering hole, the medical journal itself.
Just as pharmaceuticals fund studies and pay...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...